Will Going Private Jeopardize Simcere’s Status As A Partner Of Choice For Big Pharma?
This article was originally published in PharmAsia News
Executive Summary
Among U.S-listed Chinese pharmaceutical companies, Simcere has been ahead of the curve in snatching up deals with multinationals. As the Nanjing-based company gets closer to going private, could that status be a concern for potential suitors?
You may also be interested in...
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development
China Braces As Trump Orders 'Buy American' For Essential Medicines
As the largest manufacturer of active pharmaceutical ingredients globally, China is bracing for more uncertainty amid the global pandemic and fast-changing environment, particularly in the US.
Need a specific report? 1000+ reports available
Buy Reports